Journal of Clinical Epidemiology
Volume 59, Issue 3 , Pages 224-233 , March 2006

An unadjusted NNT was a moderately good predictor of health benefit

  • Christopher A.K.Y. Chong

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • ,
  • George Tomlinson

      Affiliations

    • Department of Biostatistics, University of Toronto, Ontario, Canada
    • Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Lisa Chodirker

      Affiliations

    • Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Nassi Figdor

      Affiliations

    • Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Mark Uster

      Affiliations

    • Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Gary Naglie

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Department of Biostatistics, University of Toronto, Ontario, Canada
    • Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • University Health Network, Toronto General Hospital, 200 Elizabeth Street, ES-14 207, Toronto, Ontario M5G 2C4, Canada
    • Geriatrics Program, Toronto Rehabilitation Institute, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Murray D. Krahn

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Department of Biostatistics, University of Toronto, Ontario, Canada
    • Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
    • University Health Network, Toronto General Hospital, 200 Elizabeth Street, ES-14 207, Toronto, Ontario M5G 2C4, Canada
    • Geriatrics Program, Toronto Rehabilitation Institute, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Tel.: 416-340-4155; fax: 416-595-5826.

,Accepted 8 August 2005.

References 

  1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733
  2. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practise and teach EBM. 2nd ed.. Edinburgh: Churchill Livingstone; 2000;
  3. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Evidence-Based Medicine Working Group. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA. 2000;283:2829–2836
  4. Cordell WH. Number needed to treat (NNT). Ann Emerg Med. 1999;33:433–436
  5. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?. Ann Intern Med. 1992;117:916–921
  6. Laupacis A, Sackett DL, Roberts RS. Therapeutic priorities of Canadian internists. CMAJ. 1990;142:329–333
  7. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002;287:2813–2814
  8. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712–720
  9. Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB. Number needed to treat: easily understood and intuitively meaningful? Theoretical considerations and a randomized trial. J Clin Epidemiol. 2002;55:888–892
  10. Sheridan SL, Pignone PM, Carmen LL. A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med. 2003;18:884–892
  11. Sheridan SL, Pignone M. Numeracy and the medical student's ability to interpret data. Eff Clin Pract. 2002;5:35–40
  12. Lesaffre E, Pledger G. A note on the number needed to treat. Control Clin Trials. 1999;20:439–447
  13. Herbert RD. How to estimate treatment effects from reports of clinical trials. II: Dichotomous outcomes. Aust J Physiother. 2000;46:309–313
  14. Flaherty RJ. A simple method for evaluating the clinical literature. Fam Pract Manag. 2004;11:47–52
  15. Livingston GK, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry. 2000;15:203–207
  16. NNT Tables [database on the Internet]. Toronto (ON): Centre for Evidence Based Medicine, University Health Network, 2003. Available at: http://www.cebm.utoronto.ca/glossary/nnts.htm#table.
  17. Cook RJS, David L. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452–454
  18. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54:253–262
  19. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5:559–575
  20. McGregor M. Cost-utility analysis: use QALYs only with great caution. CMAJ. 2003;168:433–434
  21. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976–1997. Ann Intern Med. 2000;132:964–972
  22. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993;31(7 Suppl):JS1–JS11JS18–149
  23. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36(5 Suppl):MS1–MS9MS18–147
  24. Victorian Infant Collaborative Study Group . Economic outcome for intensive care of infants of birthweight 500–999 g born in Victoria in the post surfactant era. J Paediatr Child Health. 1997;33:202–208
  25. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?. Cancer. 1996;77:1854–1861
  26. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855–865
  27. Boyle MH, Torrance GW, Sinclair JC, Horwood SP. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med. 1983;308:1330–1337
  28. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 1994;86:424–430
  29. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997;17:298–307
  30. Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model. Circulation. 1994;89:1859–1874
  31. Cronenwett JL, Birkmeyer JD, Nackman GB, Fillinger MF, Bech FR, Zwolak RM, et al. Cost-effectiveness of carotid endarterectomy in asymptomatic patients. J Vasc Surg. 1997;25:298–309discussion 310–1
  32. Desch CE, Hillner BE, Smith TJ, Retchin SM. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol. 1993;11:777–782
  33. Rose DN, Schechter CB, Silver A. Cost effectiveness of isoniazid chemoprophylaxis. In:  Goldbloom RB,  Lawrence RS editor. Preventing disease: beyond the rhetoric. New York: Springer-Verlag; 1990;p. 446–454
  34. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care. 1997;20:735–744
  35. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275:1247–1251
  36. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839–1845
  37. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6:267–274
  38. Glotzer DE, Freedberg KA, Bauchner H. Management of childhood lead poisoning: clinical impact and cost-effectiveness. Med Decis Making. 1995;15:13–24
  39. Goodnough LM, Grishaber JE, Birkmeyer JD, Monk TG, Catalona WJ. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology. 1994;44:226–231
  40. Goodwin PJ, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol. 1988;6:1537–1547
  41. Goossens ME, Rutten-van Molken MP, Leidl RM, Bos SG, Vlaeyen JW, Teeken-Gruben NJ. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. J Rheumatol. 1996;23:1246–1254
  42. Hatziandreu EI, Koplan JP, Weinstein MC, Caspersen CJ, Warner KE. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health. 1988;78:1417–1421
  43. Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics. 1994;5:249–268
  44. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA. 1992;267:2055–2061
  45. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997;15:2351–2358
  46. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996;86:1442–1445
  47. Hummel S, Piercy J, Wright R, Davie A, Bagust A, McMurray J. An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study: application to the United Kingdom. Pharmacoeconomics. 1997;12(2 Pt 1):182–192
  48. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics. 1996;9(Suppl 2):8–22
  49. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321–330
  50. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials. 1995;16:17–40
  51. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125:541–548
  52. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens. 1991;9:199–208
  53. Kellett J, Clarke J. Comparison of “accelerated” tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction. Med Decis Making. 1995;15:297–310
  54. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 1997;127:866–874
  55. King JT, Sperling MR, Justice AC, O'Connor MJ. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg. 1997;87:20–28
  56. Kitchen WH, Bowman E, Callanan C, Campbell NT, Carse EA, Charlton M, et al Victorian Infant Collaborative Study Group. The cost of improving the outcome for infants of birthweight 500–999 g in Victoria. J Paediatr Child Health. 1993;29:56–62
  57. Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia. 1997;38:154–163
  58. Launois R, Henry B, Marty JR, Gersberg M, Lassale C, Benoist M, et al. Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation: a cost and quality-of-life evaluation. Pharmacoeconomics. 1994;6:453–463
  59. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996;10:504–521
  60. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–242
  61. Lawler FH, Bisonni RS, Holtgrave DR. Circumcision: a decision analysis of its medical value. Fam Med. 1991;23:587–593
  62. Levin LA, Jonsson B. Cost-effectiveness of thrombolysis: a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J. 1992;13:2–8
  63. Malter AD, Larson EB, Urban N, Deyo RA. Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc. Spine. 1996;21:1048–1054discussion 1055
  64. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:15–21
  65. Nichol G, Laupacis A, Stiell IG, O'Rourke K, Anis A, Bolley H, et al. Cost-effectiveness analysis of potential improvements to emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med. 1996;27:711–720
  66. Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma: results from a randomised controlled trial. Pharmacoeconomics. 1997;12:89–103
  67. Nussbaum ES, Heros RC, Erickson DL. Cost-effectiveness of carotid endarterectomy. Neurosurgery. 1996;38:237–244
  68. Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, Shear NH. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996;18:160–182
  69. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol. 1997;66:454–463
  70. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;25:1149–1156
  71. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 1997;157:1972–1980
  72. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV-prevention skills training for men who have sex with men. AIDS. 1997;11:347–357
  73. Zeckhauser RJ, Shepard D. Where now for saving lives?. Law Contemp Probl. 1976;40:5–45
  74. Randolph AG, Washington AE, Prober CG. Cesarean delivery for women presenting with genital herpes lesions: efficacy, risks, and costs. JAMA. 1993;270:77–82
  75. Schneider T, Fagnani F, Lanoe JL, Hourmant M, Soulillou JP. Economic analysis of an immunosuppressive strategy in renal transplantation. Health Policy. 1988;9:75–89
  76. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J, et al. FIRST Investigators. Flolan International Randomized Survival Trial. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. Int J Technol Assess Health Care. 1996;12:698–713
  77. Sculpher M, Michaels J, McKenna M, Minor J. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care. 1996;12:104–125
  78. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J. 1991;12:694–699
  79. Smith RD, Hall J, Gurney H, Harnett PR. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Med J Aust. 1993;158:319–322
  80. Smith KJ, Pesce RR. Pulmonary artery catheterization in exacerbations of COPD requiring mechanical ventilation: a cost-effectiveness analysis. Respir Care. 1994;39:961–967
  81. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology. 1997;112:473–482
  82. Tousignant P, Cosio MG, Levy RD, Groome PA. Quality adjusted life years added by treatment of obstructive sleep apnea. Sleep. 1994;17:52–60
  83. Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease: a lifetime cost-utility analysis. Pharmacoeconomics. 1997;11:444–453
  84. Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26:914–919
  85. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FF. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant. 1995;16:463–470
  86. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325:81–86
  87. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995;122:664–675
  88. Zbrozek AS, Cantor SB, Cardenas MP, Hill DP. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm. 1994;51:1555–1563
  89. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia . Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med. 1988;319:902–907
  90. Early Breast Cancer Trialists' Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:1–15
  91. investigators GUSTO. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  92. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  93. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study . Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421–1428
  94. Centers for Disease Control and Prevention (CDC) . Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood: France, United Kingdom, and United States, January 1988–Auguest 1994. MMWR Morb Mortal Wkly Rep. 1995;44:929–933
  95. Nordic Myeloma Study Group . Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med. 1996;124:212–222
  96. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25–40[Erratum in: J Clin Psychopharmacol 1993;13:149]
  97. Denis LJ, Carnelro de Moura JL, Bono A, et al. EORTC GU Group and EORTC Data Center. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology. 1993;42:119–129discussion 129–30
  98. Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 1987;107:451–458
  99. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc. 1970;26:28–106
  100. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093–1099
  101. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–507
  102. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578–581
  103. Hourmant M, Soulillou JP, Remi JP, Sagniez G, Guenel J. [Use of cyclosporin A after antilymphocyte serum in renal transplantation]. In French. Presse Med. 1985;14:2093–2096
  104. Kelly JA, Murphy DA, Washington CD, Wilson TS, Koob JJ, Davis DR, et al. The effects of HIV/AIDS intervention groups for high-risk women in urban clinics. Am J Public Health. 1994;84:1918–1922
  105. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  106. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):99–118
  107. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  108. Mckenna WJ, Swedberg K, Zannad F, et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: results of FIRST. [Abstract] Eur Heart J. 1994;15:36A
  109. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol. 1994;89:692–698
  110. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  111. Nichol G, Detsky AS, Stiell IG, O'Rourke K, Wells G, Laupacis A. Effectiveness of emergency medical services for victims of out-of-hospital cardiac arrest: a metaanalysis. Ann Emerg Med. 1996;27:700–710
  112. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. The Copenhagen AFASAK study. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1(8631):175–179
  113. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992;327:669–677
  114. Simoons ML, Vos J, Tijssen JG, Vermeer F, Verheugt FW, Krauss XH, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol. 1989;14:1609–1615
  115. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, et al. Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;334:1491–1497
  116. Valdiserri RO, Lyter DW, Leviton LC, Callahan CM, Kingsley LA, Rinaldo CR. AIDS prevention in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction interventions. AIDS. 1989;3:21–26
  117. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, et al Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995;332:1045–1051
  118. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, Rutten-van Molken MP, Pelt RA, van Eek H, et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. J Rheumatol. 1996;23:1237–1245
  119. Weber H. Lumbar disc herniation: a controlled, prospective study with ten years of observation. Spine. 1983;8:131–140
  120. Centor RM. Signal detectability: the use of ROC curves and their analyses. Med Decis Making. 1991;11:102–106
  121. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem. 1993;30(Pt 6):521–539
  122. Krahn MD, Naglie G, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 4. Analyzing the model and interpreting the results. Med Decis Making. 1997;17:142–151

PII: S0895-4356(05)00296-9

doi: 10.1016/j.jclinepi.2005.08.005

Journal of Clinical Epidemiology
Volume 59, Issue 3 , Pages 224-233 , March 2006

Article Tools

* Image Usage & Resolution